
|Videos|January 21, 2022
The Mechanism of Action of Inclisiran for LDL-C Management in ASCVD
Norman Lepor, MD, a cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), discussed inclisiran’s mechanism of action and how it supports LDL-C management for patients with ASCVD.
Advertisement
Pharmacy Times interviewed Norman Lepor, MD, a Los Angeles-based cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), on the burden of atherosclerotic cardiovascular disease (ASCVD) and low-density lipoprotein cholesterol (LDL-C) management.
During the discussion, Lepor explained inclisiran’s mechanism of action and how it supports LDL-C management for patients with ASCVD.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Clots, Catheters, and Clinical Pearls: Pulmonary Embolism Updates for Practicing Pharmacists
2
Medicare's New GLP-1 Bridge Program: What Pharmacists Need to Know Before Dispensing
3
Isatuximab Wins FDA Approval, Becoming Second Subcutaneous Anti-CD38 for Multiple Myeloma
4
The Weekly Dose: Rising Cyclosporiasis Cases, Psychedelic Therapy Safety Monitoring, and New FDA Approvals
5











































































































